An Update on the Current Management of Hepatitis B Virus in Special Populations

Main Article Content

Phillip Huang Chen Steven-Huy Han

Abstract

Hepatitis B (HBV) in special populations within this article is considered as acute on chronic liver failure due to HBV, coinfection with Hepatitis C (HCV), Hepatitis D (HDV), or Human Immunodeficiency Virus (HIV), and HBV infection in patients who are in immunosuppressive states due to specific therapies and liver transplant recipients. Patients within these special populations are at higher risk of liver-related complications such as fibrosis, accelerated cirrhosis, acute on chronic liver failure, and/or development of hepatocellular carcinoma (HCC). Given their respective complex pathophysiology, specific treatment approaches are required for each population. With the introduction of effective antiviral HBV therapies over the past decade and the respective treatment options for the special population diseases, patient outcomes have seen improvement. With the advent of HCV direct antivirals, treatment of HBV-HCV coinfection has been more successful and consistently shown high rates of sustained virologic response. Treatment of HBV-HDV coinfection remains primarily as interferon-based, though new promising therapies have shown greater improvement in viral suppression. HBV-HIV coinfection has also shown promising results given overlapping mechanisms for treatment and specific regimens should be chosen to decrease risk of resistance. HBV reactivation in patients undergoing immunosuppressive therapies have been reported and guidelines recommend close monitoring and in certain cases, HBV antiviral therapy prophylaxis. With the effective HBV therapies, the perception of HBV as a contraindication for liver transplant has been diminishing and prolonged graft survival with effective antiviral therapies have shown promising outcomes.

Article Details

How to Cite
CHEN, Phillip Huang; HAN, Steven-Huy. An Update on the Current Management of Hepatitis B Virus in Special Populations. Medical Research Archives, [S.l.], v. 10, n. 11, nov. 2022. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/3315>. Date accessed: 02 mar. 2024. doi: https://doi.org/10.18103/mra.v10i11.3315.
Section
Research Articles

References

1. Lee WM. Acute liver failure. Semin Respir Crit Care Med. 2012;33(1):36-45. doi:10.1055/S-0032-1301733
2. Lee WM. Acute liver failure in the United States. Semin Liver Dis. 2003;23(3):217-226. doi:10.1055/S-2003-42641
3. Lee HC. Acute liver failure related to hepatitis B virus. Hepatol Res. 2008;38 Suppl 1(SUPPL. 1). doi:10.1111/J.1872-034X.2008.00420.X
4. Shakil AO, Kramer D, Mazariegos G V., Fung JJ, Rakela J. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl. 2000;6(2):163-169. doi:10.1002/LT.500060218
5. Wu T, Li J, Shao L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut. 2018;67(12). doi:10.1136/GUTJNL-2017-314641
6. Li H, Chen LY, Zhang NN, et al. Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis B. Sci Rep. 2016;6. doi:10.1038/SREP25487
7. Wai CT, Fontana RJ, Polson J, et al. Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat. 2005;12(2):192-198. doi:10.1111/J.1365-2893.2005.00581.X
8. Steinmüller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology. 2002;35(6):1528-1535. doi:10.1053/jhep.2002.33681
9. Tillmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat. 2006;13(4):256-263. doi:10.1111/J.1365-2893.2005.00695.X
10. Wiegand J, Wedemeyer H, Franke A, et al. Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial. J Viral Hepat. 2014;21(10):744-750. doi:10.1111/JVH.12210
11. Chen CH, Lin CL, Hu TH, et al. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. J Hepatol. 2014;60(6):1127-1134. doi:10.1016/J.JHEP.2014.02.013
12. Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology. 2011;53(3):774-780. doi:10.1002/HEP.24109
13. Li J, Hu C, Chen Y, et al. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. BMC Infect Dis. 2021;21(1). doi:10.1186/S12879-021-06237-X
14. Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68(4):672-681. doi:10.1016/J.JHEP.2017.11.039
15. Thompson AJV, Ayres A, Yuen L, et al. Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol. 2007;22(7):1078-1085. doi:10.1111/J.1440-1746.2006.04630.X
16. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology. 2006;44(6):1656-1665. doi:10.1002/HEP.21422
17. Chen J feng, Chen S ru, Lei Z ying, et al. Safety and efficacy of Thymosin α1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial. Hepatol Int. 2022;16(4). doi:10.1007/S12072-022-10335-6
18. Tong J, Wang H, Xu X, et al. Granulocyte Colony-Stimulating Factor Accelerates the Recovery of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure by Promoting M2-Like Transition of Monocytes. Front Immunol. 2022;13. doi:10.3389/FIMMU.2022.885829
19. Peters MG. Special populations with hepatitis B virus infection. Hepatology. 2009;49(5 Suppl). doi:10.1002/HEP.22965
20. Abdelaal R, Yanny B, El Kabany M. HBV/HCV Coinfection in the Era of HCV-DAAs. Clin Liver Dis. 2019;23(3):463-472. doi:10.1016/J.CLD.2019.04.003
21. Gaeta GB, Stornaiuolo G, Precone DF, et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol. 2003;39(6):1036-1041. doi:10.1016/S0168-8278(03)00470-7
22. Kaklamani E, Trichopoulos D, Tzonou A, et al. Hepatitis B and C Viruses and Their Interaction in the Origin of Hepatocellular Carcinoma. JAMA. 1991;265(15):1974-1976. doi:10.1001/JAMA.1991.03460150078027
23. Chiaramonte M, Stroffolini T, Vian A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer. 1999;85(10):2132-2137.
24. Chen G, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. Hepatology. 2017;66(1):13-26. doi:10.1002/HEP.29109
25. Doi A, Sakamori R, Tahata Y, et al. Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort. Hepatol Res. 2017;47(13):1438-1444. doi:10.1111/HEPR.12919
26. Sulkowski MS, Chuang WL, Kao JH, et al. No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection. Clin Infect Dis. 2016;63(9):1202-1204. doi:10.1093/CID/CIW507
27. Liu CJ, Chuang WL, Sheen IS, et al. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. Gastroenterology. 2018;154(4):989-997. doi:10.1053/J.GASTRO.2017.11.011
28. Pockros PJ. Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection. Gastroenterol Hepatol (N Y). 2017;13(9):536. PMID 29038644
29. Mavilia MG, Wu GY. HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation. J Clin Transl Hepatol. 2018;6(3):296. doi:10.14218/JCTH.2018.00016
30. Sagnelli E, Sagnelli C, Macera M, Pisaturo M, Coppola N. An update on the treatment options for HBV/HCV coinfection. Expert Opin Pharmacother. 2017;18(16):1691-1702. doi:10.1080/14656566.2017.1398233
31. Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol. 2020;73(3):523-532. doi:10.1016/J.JHEP.2020.04.008
32. Peters MG. Special populations with hepatitis B virus infection. Hepatology. 2009;49(5 Suppl). doi:10.1002/HEP.22965
33. Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of Acute Hepatitis C Virus Superinfection in Patients with Chronic Hepatitis B Virus Infection. Gastroenterology. 2004;126(4):1024-1029. doi:10.1053/j.gastro.2004.01.011
34. Zhou K, Terrault N. Management of hepatitis B in special populations. Best Pract Res Clin Gastroenterol. 2017;31(3):311-320. doi:10.1016/j.bpg.2017.06.002
35. Rosina F, Pintus C, Meschievitz C, et al. A randomized controlled trial of a 12-month course of recombinant human interferon-α in chronic delta (type D) hepatitis: A multicenter Italian study. Hepatology. 1991;13(6):1052-1056. doi:10.1002/HEP.1840130608
36. Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med. 1994;330(2):88-94. doi:10.1056/NEJM199401133300202
37. Koh C, Da BL, Glenn JS. HBV/HDV Coinfection: Emerging therapeutic options for a challenging disease. Clin Liver Dis. 2019;23(3):557. doi:10.1016/J.CLD.2019.04.005
38. Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon α therapy of chronic hepatitis D: Regression of advanced hepatic fibrosis. Gastroenterology. 2004;126(7):1740-1749. doi:10.1053/j.gastro.2004.03.017
39. Yurdaydin C, Bozkaya H, Önder FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat. 2008;15(4):314-321. doi:10.1111/J.1365-2893.2007.00936.X
40. Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006;44(3):713-720. doi:10.1002/HEP.21296
41. Keskin O, Wedemeyer H, Tüzün A, et al. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. Clin Gastroenterol Hepatol. 2015;13(13):2342-2349.e2. doi:10.1016/J.CGH.2015.05.029
42. Gordon LB, Shappell H, Massaro J, et al. Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome. JAMA. 2018;319(16):1687-1695. doi:10.1001/JAMA.2018.3264
43. Bogomolov P, Alexandrov A, Voronkova N, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J Hepatol. 2016;65(3):490-498. doi:10.1016/J.JHEP.2016.04.016
44. Wedemeyer H, Bogomolov P, Blank A, et al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection. J Hepatol. 2018;68:S3. doi:10.1016/S0168-8278(18)30224-1
45. Yurdaydin C, Keskin O, Kalkan Ç, et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study. Hepatology. 2018;67(4):1224-1236. doi:10.1002/HEP.29658
46. Yurdaydin C, Keskin O, Yurdcu E, et al. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. Hepatology. 2022;75(6):1551-1565. doi:10.1002/HEP.32259
47. Spradling PR, Richardson JT, Buchacz K, Moorman AC, Brooks JT. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996-2007. J Viral Hepat. 2010;17(12):879-886. doi:10.1111/J.1365-2893.2009.01249.X
48. Konopnicki D, Mocroft A, De Wit S, et al. Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. Aids. 2005;19(6):593-601. doi:10.1097/01.aids.0000163936.99401.fe
49. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis. 1991;163(5):1138-1140. doi:10.1093/INFDIS/163.5.1138
50. Gilson RJC, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: Effects on the natural history of infection. Aids. 1997;11(5):597-606. doi:10.1097/00002030-199705000-00007
51. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology. 2009;49(S5):S138-S145. doi:10.1002/HEP.22883
52. Sahasrabuddhe V V., Shiels MS, McGlynn KA, Engels EA. The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2012;118(24):6226-6233. doi:10.1002/CNCR.27694
53. Sheldon J, Camino N, Rodés B, et al. Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir: https://doi.org/101177/135965350501000612. 2005;10(6):727-734. doi:10.1177/135965350501000612
54. De Vriessluijs TEMS, Reijnders JGP, Hansen BE, et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology. 2010;139(6):1934-1941. doi:10.1053/J.GASTRO.2010.08.045
55. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med. 2007;356(25):2614-2621. doi:10.1056/NEJMOA067710
56. Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16(1):43-52. doi:10.1016/S1473-3099(15)00348-5
57. Gallant J, Brunetta J, Crofoot G, et al. Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults. J Acquir Immune Defic Syndr. 2016;73(3):294. doi:10.1097/QAI.0000000000001069
58. Gantner P, Cotte L, Allavena C, et al. Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection. PLoS One. 2019;14(4). doi:10.1371/JOURNAL.PONE.0215464
59. Kaplan JE, Benson C, Holmes KK, Brooks JT. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recommendations and Reports. Published 2009. Accessed September 10, 2022. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5804a1.htm
60. Matthews G V., Seaberg EC, Avihingsanon A, et al. Patterns and Causes of Suboptimal Response to Tenofovir-Based Therapy in Individuals Coinfected With HIV and Hepatitis B Virus. Clin Infect Dis. 2013;56(9):e87-e94. doi:10.1093/CID/CIT002
61. Kim HN, Rodriguez C V., Van Rompaey S, et al. Factors Associated with Delayed Hepatitis B Viral Suppression on Tenofovir Among HBV-HIV Coinfected Patients in the CNICS Cohort. J Acquir Immune Defic Syndr. 2014;66(1):96. doi:10.1097/QAI.0000000000000126
62. Yeo W, Chan PKS, Zhong S, et al. Frequency of Hepatitis B Virus Reactivation in Cancer Patients Undergoing Cytotoxic Chemotherapy: A Prospective Study Of 626 Patients With Identification of Risk Factors. Vol 62.; 2000.
63. Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100(1):182-188. doi:10.1016/0016-5085(91)90599-G
64. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004;90(7):1306-1311. doi:10.1038/SJ.BJC.6601699
65. Perrillo RP, Martin P, Lok AS. Preventing Hepatitis B Reactivation Due to Immunosuppressive Drug Treatments. JAMA. 2015;313(16):1617-1618. doi:10.1001/JAMA.2015.2571
66. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy. Gastroenterology. 2015;148(1):215-219. doi:10.1053/J.GASTRO.2014.10.039
67. Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312(23):2521-2530. doi:10.1001/JAMA.2014.15704
68. Toka B, Koksal AS, Eminler AT, Tozlu M, Uslan MI, Parlak E. Comparison of Tenofovir Disoproxil Fumarate and Entecavir in the Prophylaxis of HBV Reactivation. Dig Dis Sci. 2021;66(7):2417-2426. doi:10.1007/S10620-020-06506-W
69. Wang HS, Han SHB. Management of hepatitis B in special patient populations. Clin Liver Dis. 2010;14(3):505-520. doi:10.1016/j.cld.2010.05.002
70. Todo S, Demetris AJ, van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic Liver Transplantation for Patients with Hepatitis B Virus–related Liver Disease. Hepatology. 1991;13(4):619. doi:10.1002/hep.1840130402
71. Davies SE, Portmann BC, O′grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology. 1991;13(1):150-157. doi:10.1002/HEP.1840130122
72. Burra P, Germani G, Adam R, et al. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol. 2013;58(2):287-296. doi:10.1016/J.JHEP.2012.10.016
73. Cholongitas E, Goulis I, Antoniadis N, et al. New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence. Transpl Int. 2014;27(10):1022-1028. doi:10.1111/TRI.12370
74. Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus PW. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl. 2013;19(3):268-274. doi:10.1002/LT.23600
75. Fung J, Wong T, Chok K, et al. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years. Hepatology. 2017;66(4):1036-1044. doi:10.1002/HEP.29191
76. Teperman LW, Poordad F, Bzowej N, et al. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl. 2013;19(6):594-601. doi:10.1002/LT.23628
77. Saab S, Song D, Challita YP, et al. Long-term outcomes with oral therapy in liver transplant recipients with hepatitis B. Clin Transplant. 2019;33(12). doi:10.1111/CTR.13740
78. De Simone P, Romagnoli R, Tandoi F, et al. Early introduction of subcutaneous hepatitis B immunoglobulin following liver transplantation for hepatitis B virus infection: A prospective, multicenter study. Transplantation. 2017;100(7):1507-1512. doi:10.1097/TP.0000000000001171
79. Idilman R, Akyildiz M, Keskin O, et al. The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence. Clin Transplant. 2016;30(10):1216-1221. doi:10.1111/CTR.12804